ClinicalTrials.gg
CompletedNCT07361354ATLASUpdated Sep 10, 2026

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

A Phase 1 interventional study of AGA2118 in Healthy Participants and Pharmacokinetic Study, sponsored by Angitia Incorporated Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Angitia Incorporated Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants

Read the detailed description

This Phase 1 ethnobriding study will evaluate the pharmacokinetics, pharmacodynamics, and safety of AGA2118 in Japanese, Chinese, and Caucasian participants. Participants will be administered AGA2118 at the start of the study and followed for 85 days.

02

Conditions studied

  • Healthy Participants
  • Pharmacokinetic Study

Keywords

  • Ethnobridging
  • Healthy volunteer
03

In context

Lead sponsor

Angitia Incorporated Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females, aged 18 to 65 years
  • 25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study
  • Meet the criteria for Japanese, Chinese, or Caucasian ethnicity

Exclusion criteria

Exclusion Criteria:

  • Participating or have participated in another clinical trial within the past 6 months
  • Any bone fracture within the past 6 months
  • History of myocardial infarction or stroke within the past 12 months
  • within the past 5 years
  • Current hyper- or hypocalcemia
  • Pregnant or breastfeeding women, or women planning to become pregnant during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Japanese)

    One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of low dose AGA2118.

    Drug: AGA2118

  • Experimental
    Cohort 2 (Japanese)

    One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of medium dose AGA2118.

    Drug: AGA2118

  • Experimental
    Cohort 3 (Japanese)

    One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of high dose AGA2118.

    Drug: AGA2118

  • Experimental
    Cohort 4 (Caucasian)

    Healthy Caucasian participants will receive a single administration of high dose AGA2118.

    Drug: AGA2118

  • Experimental
    Cohort 5 (Chinese)

    Healthy Chinese participants will receive a single administration of high dose AGA2118.

    Drug: AGA2118

Interventions

  • Participants will receive AGA2118 administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax)

    Cmax of AGA2118 after dosing

    Time frame: Day 1 to up to the end of study (85 days post-dose)

  2. Time to maximum concentration (Tmax)

    Tmax of AGA2118 after dosing

    Time frame: Day 1 to up to the end of study (85 days post-dose)

  3. Area under the concentration-time curve (AUC)

    AUC of AGA2118 after dosing

    Time frame: Day 1 to up to the end of study (85 days post-dose)

  4. Half-life (t1/2)

    t1/2 of AGA2118 after dosing

    Time frame: Day 1 to up to the end of study (85 days post-dose)

  5. Clearance (CL)

    CL of AGA2118 after dosing

    Time frame: Day 1 to up to the end of study (85 days post-dose)

  6. Volume of distribution (Vd)

    Vd of AGA2118 after dosing

    Time frame: Day 1 to up to the end of study (85 days post-dose)

Secondary outcomes

  1. Treatment-emergent adverse events (TEAEs)

    Occurrence of TEAEs

    Time frame: Baseline to the end of study (85 days post-dose)

07

Study locations

1 site
  • Los Angeles EPCU
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Sep 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 23, 2026
StartActual
Jan 5, 2026
Primary completionActual
Sep 5, 2026
CompletionActual
Sep 5, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07361354
Lead sponsor
Angitia Incorporated Limited
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Jan 5, 2026
Primary completion
Sep 5, 2026
Completion
Sep 5, 2026
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGA2118

Start the discussion